NasdaqCM - Nasdaq Real Time Price USD
TG Therapeutics, Inc. (TGTX)
61.18 +3.10 (+5.34%)
At close: October 30 at 4:00:00 PM EDT
61.80 +0.62 (+1.01%)
After hours: October 30 at 7:44:36 PM EDT
Trade TGTX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for TGTX
What's happening with TGTX?
Powered by Yahoo ScoutTG Therapeutics is approaching an expected, but unconfirmed, third-quarter earnings release after recent clinical updates strengthened its multiple sclerosis franchise narrative. Investors are weighing BRIUMVI’s commercial execution against early-stage azer-cel potential, valuation debates, spending risks, and unconfirmed buyout speculation.
Powered by Yahoo Scout
- Previous Close
58.08 - Open
58.15 - Bid 52.36 x 100
- Ask 69.32 x 100
- Day's Range
58.00 - 61.76 - 52 Week Range
26.76 - 61.76 - Volume
2,847,689 - Avg. Volume
1,867,320 - Market Cap (intraday)
9.366B - Beta (5Y Monthly) 1.80
- PE Ratio (TTM)
22.25 - EPS (TTM)
2.75 - Earnings Date (est.) Nov 2, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
69.71 - Motley Fool Rating Bullish
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
TGTX
105.23%
S&P 500 (^GSPC)
10.73%
1-Year Return
TGTX
79.84%
S&P 500 (^GSPC)
11.11%
3-Year Return
TGTX
727.88%
S&P 500 (^GSPC)
81.91%
5-Year Return
TGTX
95.96%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
Market Cap
9.36B
Enterprise Value
9.57B
Trailing P/E
22.25
Forward P/E
28.32
PEG Ratio (current)
0.03
Price/Sales (ttm)
12.20
Price/Book (mrq)
15.50
Enterprise Value/Revenue
11.97
Enterprise Value/EBITDA
68.63
Financial Highlights
Profitability and Income Statement
Profit Margin
55.22%
Return on Assets (ttm)
7.28%
Return on Equity (ttm)
100.28%
Revenue (ttm)
799.54M
Net Income Avi to Common (ttm)
441.49M
Diluted EPS (ttm)
2.75
Balance Sheet and Cash Flow
Total Cash (mrq)
552.25M
Total Debt/Equity (mrq)
124.89%
Levered Free Cash Flow (ttm)
59.13M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreRaising target price to $62.00
TG THERAPEUTICS INC has an Investment Rating of BUY; a target price of $62.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
What does Argus have to say about TGTX?
TG THERAPEUTICS INC has an Investment Rating of BUY; a target price of $60.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
Raising target price to $60.00
TG THERAPEUTICS INC has an Investment Rating of BUY; a target price of $60.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
Lowering target price to $57.00
TG THERAPEUTICS INC has an Investment Rating of BUY; a target price of $57.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.